

*IDS/12*  
*8/9/01*  
**PATENT**

S/N Unknown

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Lawrence L. Kunz  
Serial No.: Unknown  
Filed: Herewith  
Title: THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS

Examiner: Unknown  
Group Art Unit: Unknown  
Docket: 295.003US5

**INFORMATION DISCLOSURE STATEMENT**

BOX PATENT APPLICATION  
Commissioner for Patents  
Washington, D.C. 20231

JC979 U.S. PTO  
09/910388  
  
07/20/01

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for review in connection with the above-identified patent application. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner be returned to the Applicant.

In accordance with 37 C.F.R. § 1.98(d), copies of the listed documents are not provided as these documents were previously cited by or submitted to the U.S. Patent Office in connection with a prior U.S. application, which is relied upon for an earlier filing date under 35 U.S.C. §120.

Applicant respectfully requests consideration of these documents during prosecution of the above-identified matter. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,  
LAWRENCE L. KUNZ  
By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6959

Date

July 21, 2001

By

*Janet E. Embretson*  
Janet E. Embretson  
Reg. No. 39,665

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	
	Applicant: Lawrence L. Kunz	Filing Date: Herewith
		Group: Unknown

U.S. 910388  
05/20/01

## U. S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	3,940,422	02/24/1976	Harita et al.	260	340	01/17/74
	4,070,484	01/24/1978	Harita et al.	424	319	12/21/76
	4,093,709	06/06/1978	Sok Choi et al.	424	19	01/28/75
	4,235,988	11/25/1980	Fildes et al.	528	79	05/31/79
	4,389,330	06/21/1983	Tice et al.	427	213.36	10/06/80
	4,442,119	04/10/1984	Magarian et al.	424	274	07/26/82
	4,485,096	11/27/1984	Bell	424	95	05/26/82
	4,485,097	11/27/1984	Bell	424	95	05/25/83
	4,512,762	04/23/1985	Spears	604	21	11/23/82
	4,555,402	11/26/1985	Matsuda et al.	424	122	08/10/84
	4,577,636	03/25/1986	Spears	128	654	11/23/82
	4,675,189	06/23/1987	Kent et al.	424	490	02/08/85
	4,732,763	03/22/1988	Beck et al.	424	433	09/28/84
	4,744,981	05/17/1988	Pavanassasivam	424	85	10/14/85
	4,824,436	04/25/1989	Wolinsky	604	53	04/21/87
	4,826,672	05/02/1989	Milius et al.	424	1	06/07/85
	4,835,002	05/30/1989	Wolf et al.	426	590	07/10/87
	4,839,155	06/13/1989	Mccague	424	1	09/09/87
	4,859,585	08/22/1989	Sonnenschein et al.	435	29	04/17/86
	4,867,973	09/19/1989	Goers et al.	530	387	09/13/84
	4,879,225	11/07/1989	Morgan Jr. et al.	435	68	03/11/87
	4,879,315	11/07/1989	Magarian et al.	514	754	09/21/87
	4,897,255	01/30/1990	Fritzberg et al.	424	1	06/19/87
	4,906,452	03/06/1990	Sivam	424	10	04/28/88
	4,929,602	05/29/1990	Harker et al.	514	18	11/22/88
	4,935,415	06/19/1990	Nakano et al.	514	211	03/20/87
	4,962,091	10/09/1990	Eppstein et al.	514	2	05/23/86
	4,968,350	11/06/1990	Bindschaedler et al.	106	170	04/01/88
	4,990,538	02/05/1991	Harris et al.	514	648	08/23/89
	4,994,033	02/19/1991	Shockey et al.	604	101	05/29/89
	4,997,652	03/05/1991	Wong	424	428	05/31/89
	5,009,659	04/23/1991	Hamlin et al.	606	159	10/30/89
	5,015,578	05/14/1991	Schroeder et al.	435	119	02/20/90
	5,015,666	05/14/1991	Magarian et al.	514	754	09/22/89
	5,026,537	06/25/1991	Daddona et al.	424	1.1	05/06/89
	5,032,679	07/16/1991	Brandley et al.	536	21	08/31/89
	5,043,335	08/27/1991	Kleinschroth et al.	514	211	06/23/90
	5,047,431	09/10/1991	Schickaneder et al.	514	648	05/14/90

Examiner	Date Considered
Substitute Disclosure Statement Form (PTO-1449)	

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	
	Applicant: Lawrence L. Kunz	Filing Date: Herewith
		Group: Unknown

## U. S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,049,132	09/17/1991	Schaffer et al.	604	101	01/08/90
	5,053,033	10/01/1991	Clarke et al.	606	3	10/10/90
	5,059,166	11/22/1991	Fischell et al.	600	3	12/11/89
	5,066,789	11/19/1991	Srinivasan et al.	530	388	09/29/89
	5,073,633	12/17/1991	Schroeder et al.	540	545	11/05/90
	5,093,330	03/03/1992	Caravatti et al.	514	211	03/21/91
	5,098,903	03/24/1992	Magarian et al.	514	255	11/06/89
	5,102,402	04/07/1992	Dror et al.	604	265	01/04/91
	5,112,305	05/12/1992	Barath et al.	704	96	10/16/90
	5,114,719	05/19/1992	Sabel et al.	424	422	09/14/89
	5,116,864	05/26/1992	March et al.	514	455	04/09/91
	5,120,535	06/09/1992	Marquardt et al.	424	85.5	05/04/87
	5,140,012	08/18/1992	McGovern et al.	514	19	05/31/90
	5,166,143	11/24/1992	Ondetti et al.	514	89	06/13/91
	5,171,217	12/15/1992	March et al.	604	53	02/28/91
	5,176,617	01/05/1993	Fischell et al.	600	3	11/21/91
	5,180,366	01/19/1993	Woods	604	96	10/10/90
	5,185,260	02/09/1993	Crissman et al.	435	244	08/29/91
	5,189,046	02/23/1993	Burch et al.	514	330	08/14/90
	5,189,212	02/23/1993	Ruenitz	562	468	09/07/90
	5,192,525	03/09/1993	Yang et al.	424	11	06/28/91
	5,199,939	04/06/1993	Dake et al.	600	3	02/23/90
	5,208,019	05/05/1993	Hanson et al.	424	85	09/27/89
	5,208,238	05/04/1993	King	514	255	06/18/90
	5,213,576	05/25/1993	Abiuso et al.	604	96	06/11/91
	5,213,580	05/25/1993	Slepian et al.	623	1	03/25/92
	5,216,024	06/01/1993	Markaverich et al.	514	543	07/15/88
	5,216,126	06/01/1993	Cox et al.	530	350	06/19/91
	5,219,548	06/15/1993	Yang et al.	424	1	10/01/90
	5,221,620	06/22/1993	Purchio et al.	435	69	12/05/89
	5,226,430	07/13/1993	Spears et al.	128	898	05/24/91
	5,229,495	04/20/1993	Ichijo et al.	530	350	06/18/91
	5,232,444	08/03/1993	Just et al.	604	96	02/25/91
	5,232,911	08/03/1993	Vidal	514	12	07/23/91
	5,238,714	08/24/1993	Wallace et al.	427	213	10/02/90
	5,238,950	08/24/1993	Clader et al.	514	360	12/17/91
	5,242,397	09/07/1993	Barath et al.	604	96	01/02/92
	5,248,764	09/28/1993	Flanagan et al.	530	324	02/27/92

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003USS	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## U. S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,254,594	10/19/1993	Niikura et al.	514	648	04/08/92
	5,260,224	11/09/1993	Stossel et al.	436	503	10/10/91
	5,268,358	12/07/1993	Fretto et al.	514	12	05/06/91
	5,268,455	12/07/1993	Cianciolo	530	404	01/23/92
	5,270,047	12/14/1993	Kauffman et al.	424	422	11/21/91
	5,280,016	01/18/1994	Conrad et al.	514	56	09/03/91
	5,280,109	01/18/1994	Miyazono et al.	530	399	01/27/92
	5,282,785	02/01/1994	Shapland et al.	604	21	10/05/92
	5,283,257	02/01/1994	Gregory et al.	514	458	07/10/92
	5,284,763	02/08/1994	Derynk et al.	435	240	03/04/92
	5,284,869	02/08/1994	Bisaccia et al.	514	455	12/17/91
	5,288,711	02/22/1994	Mitchell et al.	514	56	04/28/92
	5,288,735	02/22/1994	Trager et al.	514	363	06/15/92
	5,296,492	03/22/1994	Shiozawa et al.	514	337	06/03/92
	5,304,325	04/19/1994	Kaufman et al.	252	312	11/13/91
	5,304,541	04/19/1994	Purchio et al.	514	12	03/14/91
	5,308,622	05/03/1994	Casscells et al.	424	422	07/16/92
	5,308,862	05/03/1994	Ohlstein et al.	514	411	03/05/93
	5,314,679	05/24/1994	Lewis et al.	424	9	12/22/92
	5,316,766	05/31/1994	Baldus et al.	424	94	02/06/90
	5,324,736	06/28/1994	Magarin et al.	514	317	08/16/93
	5,326,757	07/05/1994	Demopoulos	514	167	08/18/93
	5,328,471	07/12/1994	Slepian	604	101	08/04/93
	5,332,584	07/26/1994	Scher et al.	424	408	12/09/91
	5,340,925	08/23/1994	Lioubin et al.	530	395	06/17/92
	5,346,702	09/13/1994	Na et al.	424	490	12/04/92
	5,346,897	09/13/1994	King	514	290	06/10/92
	5,346,993	09/13/1994	Miyazono et al.	530	399	07/15/93
	5,354,562	10/11/1994	Platz et al.	424	489	01/16/93
	5,354,774	10/11/1994	Deckelbaum et al.	514	455	12/24/92
	5,356,713	10/18/1994	Charmot et al.	428	407	06/01/93
	5,358,844	10/25/1994	Stossel et al.	435	2	02/18/93
	5,362,424	11/08/1994	Lee et al.	264	4.3	10/10/91
	5,362,478	11/08/1994	Desai et al.	424	9	03/26/93
	5,364,632	11/15/1994	Benita et al.	424	450	03/09/93
	5,364,843	11/15/1994	King	514	15	06/10/92
	5,380,716	01/10/1995	Conrad et al.	514	56	12/28/92
	5,393,763	02/28/1995	Black et al.	514	333	01/12/94

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	
	Applicant: Lawrence L. Kunz	Filing Date: Herewith
		Group: Unknown

## U. S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,395,610	03/07/1995	King	424	10	05/28/93
	5,423,885	06/13/1995	Williams	623	1	07/14/93
	5,444,164	08/22/1995	Purchio et al.	536	23.5	05/04/92
	5,453,436	09/26/1995	Ohlstein	514	411	03/17/94
	5,458,568	10/17/1995	Racchini et al.	604	19	09/17/93
	5,460,807	10/24/1995	Cardin et al.	424	78	08/19/92
	5,462,925	10/31/1995	Ogawa et al.	514	12	11/20/92
	5,468,746	11/21/1995	Casagrande et al.	514	235.5	06/21/91
	5,512,268	04/30/1996	Grinstaff et al.	424	9.322	06/06/95
	5,527,337	06/18/1996	Stack et al.	606	198	02/01/91
	5,563,146	10/08/1996	Morris et al.	514	291	05/26/95
	5,616,608	04/01/1997	Kinsella et al.	514	449	04/18/96
	5,646,160	07/08/1997	Morris et al.	514	291	05/26/95
	5,665,728	09/09/1997	Morris et al.	514	291	05/26/95
	5,733,925	03/31/1998	Kunz et al.	514	499	10/28/96
	5,776,184	07/07/1998	Tuch	623	1	10/09/96
	5,811,447	09/22/1998	Kunz, et al.	514	411	05/25/95
	5,824,048	10/20/1998	Tuch	623	1	10/09/96
	5,945,456	08/31/1999	Grainger et al.	514	651	11/06/97
	6,074,659	06/13/2000	Kunz et al.	424	423	07/10/98
	Re. 32,944	06/06/1989	Harita et al.	562	455	06/01/77
	Re. 33,403	11/23/1990	Stolle et al.	424	87	01/13/89

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	0 260 066	03/16/1988	European	C07C	217/54		
	0 297 946	01/04/1989	European	A61K	31/40		
	0 365 863	05/02/1990	European	C07D	413/04		
	0 374 044	06/20/1990	European	C12N	15/16		
	0 411 893	02/06/1991	European	C12N	15/13		
	0 451 202	10/16/1991	European	A61K	9/70		
	0 526 102	02/03/1993	European	A61M	29/02		
	0 577 215	01/05/1993	European	A61K	9/14		
	0 606 613	07/20/1994	European	G01N	33/531		
	85/00107	01/17/1985	PCT	A61K	31/13		
	88/10259	12/29/1988	PCT	C07D	313/00		
	90/01969	03/08/1990	PCT	A61M	29/00		

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
	Applicant: Lawrence L. Kunz (Use several sheets if necessary)	Filing Date: Herewith
		Group: Unknown

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Invention Number No.	Date	Country			Translatio Yes
				Class	Subclass	
	90/11676	10/18/1990	PCT			
	90/12597	11/01/1990	PCT	A61K	47/48	
	90/13293	11/15/1990	PCT	A61K	31/40	
	91/15219	10/14/1991	PCT	A61K	37/00	
	91/15222	10/17/1991	PCT	A61K	37/02	
	91/17731	11/28/1991	PCT	A61F	7/12	
	92/08480	05/29/1992	PCT	A61K	37/36	
	92/11872	07/23/1992	PCT	A61K	47/48	
	92/11890	07/23/1992	PCT	A61M	25/00	
	92/11895	07/23/1992	PCT	A61K	31/00	
	92/18546	10/29/1992	PCT	C08B	37/10	
	92/19273	11/12/1992	PCT	A61K	49/02	
	92/21363	12/10/1992	PCT	A61K	37/02	
	93/07748	04/29/1993	PCT	A01N	43/16	
	93/11120	06/10/1993	PCT	C07D	263/62	
	93/17121	09/02/1993	PCT	C12P	17/02	
	93/24476	12/09/1993	PCT	C07D	305/14	
	94/08604	04/28/1994	PCT	A61K	37/00	
	94/08605	04/28/1994	PCT	A61K	37/00	
	94/15590	07/21/1994	PCT	A61K	9/51	
	94/16706	08/04/1994	PCT	A61K	31/535	
	94/17786	08/18/1994	PCT	A61K	9/16	
	94/18954	09/01/1994	PCT	A61K	9/48	
	94/19000	09/01/1994	PCT	A61K	37/02	
	94/19001	09/01/1994	PCT	A61K	37/02	
	94/19003	09/01/1994	PCT	A61K	37/02	
	94/25020	11/10/1994	PCT	A61K	31/335	

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	"Cytochalasins", In: The Merck Index, Eleventh Edition, Merck & Co., Rahway, NJ, 438-439 (1989).
	"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev. L/07/92.

Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Allemann, E., et al., "Drug Loaded Poly(lactic acid) Nanoparticles Produced by a Versible Salting-out Process: Purification of an Injectable Dosage Form", Eur. J. Pharm. Biopharm., 39, 13-18 (1993).

Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor B1-interluekin and B2-micorglobulin Plasma Levels", Kidney International, 40, 1110-1117 (1991).

Aschermann, M., "Restenosis after percutaneous transluminal coronary angioplasty Pathophysiology, new trends in prevention and treatment", Cor Vasa, 36, 211-218 (1994).

Assoian, et al., "Type Beta Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells", J. Cell. Biol., 102, 1217-1223 (1986).

Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions", Int'l J. Pharm., 52, 165-171 (1989).

Bagdade, J.D., et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).

Bamburg, J.R., et al., "Biological and Biochemical Actions of Trichothecene Mycotoxins", In: Progress in Molecular and Subcellular Biology, Vol. 8, Hahn, F.E., et al., (eds.), Springer-Verlag, New York, p. 41-110 (1983).

Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", JACC, 13, 252A, ( 1989).

Barbacid, M., et al., "Binding of [acetyl-14C]Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes", Euro. J. Biochem., 44, 437-444 (1974).

Beck, et al., "Poly(DL-lactide-co-glycolide)/norethisterone microacapsules: an injectible biodegradable contraceptive", Biol. Reprod., 28, 186-195 (1983).

Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antitrhombin III Levels", Breast Cancer Res. and Treatment, 12, 307-310 (1988).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Bogyo, D., et al., "Cytochalasin-B-induced Immunosuppression of Murine Allogenic Anti-Tumor Response and the Effect of Recombinant Human Interleukin-2", Cancer Immunol. Immunother., 32, 400-405 (1991).

Bousquet, P.F., et al., "Effects of Cytochalasin B in Culture In Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma", Cancer Research, 50, 1431-1439 (1990).

Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steriod Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs", J. Urology, 130, 1208-1210 (1983).

Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988).

Bumol, et al., "Unique Glycoprotein-proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells", PNAS USA 79, 1245-1249 (1982).

Butta, A., et al., "Induction of Transforming Growth Factor Beta1 in Human Breast Cancer In Vivo Following Tamoxifen Treatment", Cancer Research, 52, 4261-4164 (1992).

Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", Proc. Natl. Acad. Sci. USA, 89, 7159-7163 (1992).

Chaldakov, G.N., et al., "Cyclic AMP- and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization", Cell and Tissue Research, 255, 434-442 (1989).

Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", Cancer Res., 51, 5851-5858 (1991).

Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome", Cytokine, 3, 292-298 (1991).

Chapman, G.D., et al., "A Bioabsorbable Stent: Initial Experimental Results", Supplement III Circulation, 82, Abstract No. 0283, III-72, (1990).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Clowes, A.W., et al., "Kinetics of Cellular Proliferation after Arterial Injury -- I. Smooth Muscle Growth in the Absence of Endothelium", <u>Laboratory Investigation</u> , 49, 327-333 (1983).
Clowes, A.W., et al., "Kinetics of Cellular Proliferation after Arterial Injury -- III. Endothelium and Smooth Muscle Growth in Chronically Denuded Vessels", <u>Laboratory Investigation</u> , 54, 295-303 (1986).
Clowes, A.W., et al., "Mechanisms of Stenosis after Arterial Injury", <u>Laboratory Investigation</u> , 49, 208-21 (1983).
Clowes, A.W., et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", <u>Circulation Research</u> , 56, 139-145 (1985).
Cohen, et al., "Controlled Delivery Systems for Proteins Based on Poly(lactic/glycolic acid) Microspheres", <u>Pharmaceutical Research</u> , 8, 713-720 (1991).
Cole, R.J., et al., "The Cytochalasins", In: <u>Handbook of Toxic Fungal Metabolites</u> , Academic Press, New York, p. 264-265, 281-282 (1981).
Cowsar, et al., "Poly(actide-co-glycolide) Microcapsules for Controlled Release of Steroids", <u>Methods Enzymology</u> , 112, 101-116 (1985).
Crissman, H.A., et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G1 Phase of the Cell Cycle", <u>Proc. Natl. Acad. Sci. USA</u> , 88, 7580-7584 (1991).
Danielpour, "Improved Sandwich Enzyme-linked Immunosorbent Assays Transforming Growth Factor B1", <u>J. Immunol. Methods</u> , 158, 17-25 (1993).
Danielpour, D., et al., "Evidence for Differential Regulation of TGF-Beta1 and TGF-Beta2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays", <u>Annals N.Y. Acad. Sci.</u> , 593, 300-302 (1990).
Danielpour, D., et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF-Beta1 and TGF-Beta2) Secreted by Cells in Culture", <u>J. Cell. Physiol.</u> , 138, 79-86 (1989).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

	Dasch, J.R., et al., "Capture Immunoassays Specific for TGF-Beta1 and TGF-Beta2: Use in Pharmacokinetic Studies", <u>Annals N.Y. Acad. Sci.</u> , 593, 303-305 (1990).
	Detre, K., et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", <u>The New England Journal of Medicine</u> , 318, 265-270 (1988).
	Dimond, P.F., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes", <u>Genetic Engineering News</u> , p. 7, 19, (1993).
	Ebner, et al., "Cloning of a Type I TGF-B Receptor and Its Effect on TGF-B Binding to the Type II Receptor", <u>Science</u> , 260, 1344-1348 (1993).
	Eldridge, J.H., et al., "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies", <u>Infection and Immunity</u> , 59, 2978-2986 (1991).
	Epstein, S.E., et al., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells", <u>Circulation</u> , 84, 778-787 (1991).
	Fanelli, C., et al., "Restenosis Following Coronary Angioplasty", <u>American Heart Journal</u> , 119, 357-368 (1990).
	Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium.", <u>Br. J. Pharmacol.</u> , 107, 679-683 (1992).
	Faxon, D.P., et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", <u>Arteriosclerosis</u> , 4, 189-195 (1984).
	Fay, M.J., et al., "Effects of Cytochalasin B on the Uptake of Ascorbic Acid and Glucose by 3T3 Fibroblasts: Mechanism of Impaired Ascorbate Transport in Diabetes", <u>Life Sciences</u> , 46, 619-624 (1990).
	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", <u>Exp. Mol. Pathol.</u> , 43, 288-296 (1985).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003USS	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", <u>JACC</u> , <u>17</u> , 758-769 (1991).
Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", <u>Prog. Colloid and Polymer Sci.</u> , <u>56</u> , 16-20 (1975).
Fulop, T., et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes under Various Stimuli", <u>Immunobiol.</u> , <u>171</u> , 302-310 (1986).
Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface.", <u>J. Cell. Biol.</u> , <u>103</u> , 1699-1710 (1986).
Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", <u>International Journal of Pharmaceutics</u> , <u>69</u> , 193-196 (1991).
Gasco, M.R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection", <u>Intl. J. of Pharmaceut</u> , <u>62</u> , 119-123 (1990).
Glagov, S., et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries", <u>New England Journal of Medicine</u> , <u>316</u> , 1371-1375 (1987).
Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase.", <u>Atherosclerosis</u> , <u>65</u> , 215-225 (1987).
Grainger, D.J., et al., "A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular Smooth-Muscle Cells.", <u>Biochemical Journal</u> , <u>277</u> , 145-151 (1991).
Grainger, D.J., et al., "Heparin Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Releasing Transforming Growth Factor beta-like Activity from Serum", <u>Cardiovascular Research</u> , <u>27</u> , 2238-2247 (1993).
Grainger, D.J., et al., "Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", <u>Biochemical Journal</u> , <u>283</u> , 403-408 (1992).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

Grainger, D.J., et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth-Muscle Cells in Culture by Inducing Production of Transforming Growth Factor Beta", Biochem J. 294, 109-112 (1993).

Hanke, H., et al., "Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin", Circulation, 85, 1548-1556 (1992).

Harpel, et al., "Plasmin Catalysis Binding of Lipoprotein (A) to Immobilized Fibrinogen and Fibrin.", Proc. Natl. Acad. Sci. USA, 86, 3847-3851 (1989).

Heldin, et al., "Demonstration of an Antibody Against Platelet-Derived Growth Factor.", Exp. Cell. Res., 136, 255-261 (1981).

Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols.", J. Polymer Science, Polymer Letters Edition, 18, 293-297 (1980).

Henriksson, et al., "Hormonal Regulation of Serum Lp (a) Levels.", J. Clin. Invest., 89, 1166-1171 (1992).

Hoff, H.F., et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages", Arteriosclerosis, 9, 538-549 (1989).

Hofmann, J., et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C", Int. J. Cancer, 42, 382-388 (1988).

Holland, J.A., et al., "Atherogenic Levels of Low-Density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells", American Journal of Pathology, 140, 551-558 (1992).

Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1, and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture.", Exp. Cell Res., 200, 358-360 (1992).

Jarvis, B.B., et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica", In: Chemistry of Allelopathy: Biochemical Interactions Among Plants, ACS Symposium Series No. 268, Thompson, A.C., (ed.), 149-159 (1985).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

Jarvis, B.B., et al., "Macroyclic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance", <u>Acc. Chem. Res.</u> , <u>15</u> , 388-395 (1982).
Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues", <u>Supp. II Circulation</u> , <u>78</u> , Abstract No. 0327, page 11-82 (1988).
Jordan, V.C., et al., "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials", <u>Hormones, Cell Biology, and Cancer: Perspectives and Potentials</u> , Alan R. Liss, Inc., 105-123 (1988).
Jung, S.M., et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions", <u>Thrombosis Research</u> , <u>50</u> , 775-787 (1988).
Kambic, H., et al., "Biomaterials in Artificial Organs", <u>Chemical &amp; Engineering News</u> , <u>30</u> , 31-48, (1986).
Kemp, P.R., et al., "The Id Gene is Activated by Serum but is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells", <u>Biochemical Journal</u> , <u>277</u> , 285-288 (1991).
Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells", <u>Cell</u> , <u>48</u> , 417-428 (1987).
Koff, et al., "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-B.", <u>Science</u> , <u>260</u> , 536-538 (1993).
Kovach, J.A., et al., "Serial Intravascular Ultrasound Studies Indicate that Chronic Recoil is an Important Mechanism of Restenosis Following Transcatheter Therapy", <u>JAAC</u> , <u>21</u> , Abstract No. 835-3, p. 484A (1993).
Lafont, A.M., et al., "Post-Angioplasty Restenosis in the Atherosclerotic Rabbit: Proliferative Response or Chronic Constriction?", <u>Circulation</u> , <u>88</u> , 66th Scientific Sessions, Abstract No. 2806, p. I-521 (1993).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

\*\*Examiner  
Initial

**OTHER DOCUMENTS**  
(Including Author, Title, Date, Pertinent Pages, Etc.)

Lambert, C.R., et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs", <u>Coronary Artery Disease</u> , <u>4</u> , 469-475 (1993).
Lefer, "Role of Transforming Growth Factor Beta in Cardioprotection of the Ischemic-Reperfused Myocardium", <u>Growth Factors and the Cardiovascular System</u> , P. Cummins, ed., Kluwer Academic Publishers, 249-260 (1993).
Lefer, et al., "Mechanisms of the Cardioprotective Effect of Transforming Growth Factor B1 in Feline Myocardial Ischemia and Reperfusion", <u>PNAS (USA)</u> , <u>90</u> , 1018-1022 (1993).
Lefer, A.M., et al., "Mediation of Cardioprotection by Transforming Growth Factor Beta", <u>Science</u> , <u>249</u> , 61-64 (1990).
Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", <u>Intl. J. Pharmaceut.</u> , <u>66</u> , 29-37 (1990).
Levy, R.J., et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants", In: <u>Biotechnology and Bioactive Polymers</u> , Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268 (1994).
Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", <u>Biochimica et Biophysica Acta</u> , <u>1042</u> , 42-50 (1990).
Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and is Chemotactic for Smooth Muscle Cells in Vitro", <u>Cir. Res.</u> , <u>74</u> , 214-224 (1992).
Lin, et al., "Expression Cloning of the TGF-B Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase.", <u>Cell</u> , <u>68</u> , 775-785 (1992).
Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", <u>Drug Development and Industrial Pharmacy</u> , <u>16</u> , 899-920 (1990).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Lipski, K.M., et al., "Cytochalasin B: Preparation, Analysis in Tissue Extracts, and Pharmacokinetics after Intraperitoneal Bolus Administration in Mice", <u>Analytical Biochemistry</u> , <u>161</u> , 332-340 (1987).
Liu, M.D., et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia", <u>Circulation</u> , <u>79</u> , 1374-87 (1989).
Love, et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women.", <u>Annals of Internal Medicine</u> , <u>115</u> , 860-864 (1991).
Love, et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer", <u>J. Natl. Cancer Inst.</u> , <u>82</u> , 1327-1332 (1990).
Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", <u>J. Pharm. Pharmacol.</u> , <u>42</u> , 6P, (1990).
Manasek, F.J., et al., "The Sensitivity of Developing Cardiac Myofibrils to Cytochalasin-B", <u>Proc. Natl. Acad. Sci. USA</u> , <u>69</u> , 308-213 (1972).
Mang, T.D., "Distribution to Normal and Tumor Tissues of Cytochalasin B after Intravenous Administration in Mice", Bachelor of Science Thesis, Syracuse University, New York, (1994).
Massague, "The transforming growth factor-B family", <u>Ann. Rev. Cell Biol.</u> , <u>6</u> , 597-641 (1990).
McCaffrey, T.A., et al., "Transforming Growth Factor-beta Activity is Potentiated by Heparin via Dissociation of the Transforming Growth Factor-beta/alpha2-Macroglobulin Inactive Complex", <u>The Journal of Cell Biology</u> , <u>109</u> , 441-448 (1989).
McCaroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-B (TGF-B) by Endothelial Cells in Culture.", <u>Clin. Chem.</u> , <u>36</u> , Abstract No. 0934, 1152, (1990).
McClean, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", <u>Nature</u> , <u>330</u> , 132-137 (1987), 132-137 (1987).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention", <u>Carcinogenesis</u> , 7, 193-196 (1986).
McDonald, et al., "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial.", <u>B. Med. J.</u> , 303, 435-437 (1991).
McQuiggan, J.D., "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and Microencapsulated Injection in Mice and its Effect on beta-N-Acetylglucosaminidase Activity in Cultured B16-BL6 Melanoma Cells", Masters' Thesis, Syracuse University, New York, 41 p., (1988).
Merrilees, et al., "Synthesis of TGF-B1 by Vascular Endothelial Cells is Correlated with Cell Spreading.", <u>J. Vasc. Res.</u> , 29, 376-384 (1992).
Middlebrook, J.L., et al., "Specific Association of T-2 Toxin with Mammalian Cells", <u>Biochemical Pharmacology</u> , 38, 3093-3102 (1989).
Morisaki, et al., "Effects of transforming growth factor-B, on growth of aortic smooth muscle cells", <u>Atherosclerosis</u> , 88, 227-234 (1991).
Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", <u>Science</u> , 244, 1342-1344 (1989).
Naito, M., et al., "Vascular Endothelial Cell Migration In Vitro: Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System", <u>Artery</u> , 17, 21-31 (1989).
Nakao, J., et al., "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid", <u>Atherosclerosis</u> , 46, 309-319 (1983).
Nikol, S., et al., "Expression of Transforming Growth Factor Beta 1 is Increased in Human Vascular Restenosis Lesions", <u>J. Clin. Invest.</u> , 90, 1582-1592 (1992).
O'Brien, et al., "Osteopontin mRNA and Protein are Overexpressed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification.", <u>Circulation</u> , 88, Abstract No. 3330, I-609, (1993).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

O'Connor-McCourt, et al., "Latent Transforming Growth Factor-B in Serum: A Specific Complex with a2-macroglobin", <u>J. Biol. Chem.</u> <u>262</u> , 14090-14099, (1987).
Ohmi, K., et al., "Effect of K252a, A protein kinase inhibitor, on the proliferation of vascular smooth muscle cells", <u>Biochemical and Biophysical Research Communications</u> , <u>173</u> (3), 976-981 (1990).
Oliveira, M.M., et al., "Isolation and Characterization of Smooth Muscle Cell Membranes", <u>Biochimica et Biophysica Acta</u> , <u>332</u> , 221-232 (1974).
Osborne, et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Transdermal Studies of a Model Hydrophilic Drug", <u>J. Pharm. Pharmacol.</u> , <u>43</u> , 451-454 (1991).
Osipow, "Transparent Emulsion", <u>J. Soc. Cosmetic Chemists</u> , 277-285 (1963).
Pardee, A.B., et al., "Control of Cell Proliferation", <u>Cancer</u> , <u>39</u> , 2747-2754 (1977).
Pathak, et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", <u>International Journal of Pharmaceutics</u> , <u>65</u> , 169-175 (1990).
Podzimek, et al., "O/W Microemulsions", <u>J. Dispersion Science and Technology</u> , <u>I</u> , 341-359 (1980).
Popma, J.J., et al., "Factors Influencing Restenosis after Coronary Angioplasty", <u>The American Journal of Medicine</u> , <u>88</u> , 1-16N--1-24N, (1990).
Post, M.J., et al., "Restenosis is Partly Due to Intimal Hyperplasia and Partly to Remodeling of the Injured Arterial Wall", <u>European Heart Journal</u> , Abstract No. P1164, p. 201, (1993).
Post, M.J., et al., "Which Part of the Angiographic Diameter Reduction After Balloon Dilation is Due to Intimal Hyperplasia?", <u>JACC</u> , <u>21</u> , Abstract No. 851-95, I-36A, (1993).
Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", <u>International Journal of Pharmaceutics</u> , <u>27</u> , 335-348, (1985).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Rauterberg, J., et al., "Collagens in Atherosclerotic Vessel Wall Lesions", <u>Current Topics in Pathology</u> , 87, 163-192 (1993).
Reid, V.C., et al., "Fragmentation of DNA in P388D, Macrophages Exposed to Oxidized Low-Density Lipoprotein", <u>FEBS Letters</u> , 332, 218-220 (1993).
Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", <u>Nature</u> , 362, 801-809 (1993).
Ross, R., et al., "Chronic Inflammation, PDGF, TFTB, and Smooth Muscle Proliferation", <u>Molecular Mechanisms of Vascular Diseases</u> , Abstract No. G006, 96 (1991).
Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfant", <u>J. Dispersion Science and Technology</u> , 1 (2), 151-164 (1980).
Sanders, et al., "Controlled Release of a Lutenizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres.", <u>J. Pharmaceutical Science</u> , 73, 1294-1297 (1984).
Schlingemann, et al., "Expression of the High Molecular Weight Molema-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds.", <u>Amer. J. Pathology</u> , 136, 1393-1405 (1990).
Schneiderman, et al., "Increased Type 1 Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries.", <u>PNAS (USA)</u> , 89, 6998-7002 (1992).
Schwartz, R.S., et al., "Restenosis After Balloon Angioplasty -- A Practical Proliferative Model in Porcine Coronary Arteries", <u>Circulation</u> , 82, 2190-2200 (1990).
Schwartz, R.S., et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms", <u>JACC</u> , 20, 1284-1293, (1992).
Schwartz, S.M., et al., "Maintenance of Integrity in Aortic Endothelium", <u>Federation Proceedings</u> , 39, 2618-2625 (1980).
Shanahan, C.M., et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells", <u>Circulation Research</u> , 73, 193-204 (1993).

Examiner	Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 295.003US5	Serial No. Unknown
	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Shewmon, D.A., et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease", <u>Supplement I Circulation</u> , <u>86</u> , 1345 (1992).
Shoji, et al., "Enhancement of Anti-Inflammatory Effects of Biphenylalactic Acid by its Incorporation into Lipid Microspheres.", <u>J. Pharm. Pharmacol.</u> , <u>38</u> , 118-121 (1986).
Simpson, J.B., et al., "Percutaneous Coronary Atherectomy", <u>Circulation</u> , <u>78</u> , 61st Scientific Session, Abstract No. 0326, p. II-82, (1988).
Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay.", <u>J. Cell Biol.</u> , <u>95</u> , 667-671 (1982).
Snow, A.D., et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", <u>American Journal of Pathology</u> , <u>137</u> , 313-330 (1990).
Steele, P.M., et al., "Balloon Angioplasty -- Nature History of the Pathophysiological Response to Injury in a Pig Model", <u>Circulation Research</u> , <u>57</u> , 105-112 (1985).
Streuli, C.H., et al., "Extracellular Matrix Regulates Expression of the TGF-Beta 1 Gene", <u>J. Cell Biol.</u> , <u>120</u> , 253-260 (1993).
Suckling, K.E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature", <u>Biochemical Society Transactions</u> , <u>21</u> , 660-662 (1993).
Tamm, C., "The Antibiotic Complex of the Verrucarins and Roridins", <u>Fortschr. Chem. Org. Naturst.</u> , <u>31</u> , 61-117 (1973).
Tice, et al., "Biodegradable controlled-release parental systems", <u>Pharmaceutical Technology</u> , <u>26</u> -35 (1984).
Topol, E.J., et al., "The Restenosis "Antithesis""", <u>Mayo Clin. Proc.</u> , <u>68</u> , 88-90 (1993).
Vanhoufte, "Hypercholesterolaemia, Atherosclerosis and Release of Endothelium-Derived Relaxing Factor by Aggregating Platelets", <u>Eur. Heart J.</u> , <u>12</u> , Suppl. E, 25-32 (1991).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery.", <u>Br. J. Pharmacol.</u> , 109, 612-617 (1993).
Vijayagopal, P., et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor", <u>Biochemical Journal</u> , 289, 837-844 (1993).
Vijayagopal, P., et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholestryl Ester Accumulation in Foam Cells from Rabbit Atherosclerotic Lesions", <u>J. Clin. Invest.</u> , 91, 1011-1018 (1993).
Voisard, R., et al., "The in-vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries", <u>Coronary Artery Disease</u> , 4, 935-942 (1993).
Wakefield, et al., "Latent Transforming Growth Factor-B from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences.", <u>J. Biol. Chem.</u> , 263, 7646-7654 (1988).
Wakefield, et al., "Recombinant Latent Transforming Growth Factor-B, has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor-B, and a Different Tissue Distribution.", <u>J. Clin. Invest.</u> , 86, 1976-1984 (1990).
Weissberg, P.L., et al., "Approaches to the Development of Selective Inhibitors of Vascular Smooth Muscle Cell Proliferation", <u>Cardiovascular Research</u> , 27, 1191-1198 (1993).
Weissberg, P.L., et al., "Effects of TGF-Beta on Vascular Smooth Muscle Cell Growth", <u>In: Growth Factors and the Cardiovascular System</u> , Cummins, P., (ed.), Kluwer Academic Publishers, 189-205 (1993).
Weissberg, P.L., et al., "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Co-mitogenic with Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells", <u>Atherosclerosis</u> , 85, 257-262 (1990).
Wight, "Proteoglycans Structure and Function", <u>Cell Biol. of Extracellular Matrix, Second Edition</u> , E.D. Hay, Ed., Plenum Press, New York, 45-78 (1991).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003USS	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Wight, et al., "Cell Biology of Arterial Proteoglycans.", Arteriosclerosis, 9, 1-20 (1989).

Wight, et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation.", Current Opinion in Cell Biol., 4, 793-801 (1992).

Wilensky, R.L., et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty", American Heart Journal, 122, 1136-1140 (1991).

Wolinsky, H., et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery.", JACC, 15, 475-481 (1990).

Zuckerman, et al., "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and TGF-B.", Atherosclerosis, 96, 203-214 (1992).

Zuckerman, et al., "Exogenous Glucocorticoids Increase Macrophage Section of apo E by Cholesterol Independent Pathways.", Atherosclerosis, 103, 43-54 (1993).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.